PT  - JOURNAL ARTICLE
AU  - Yamamoto, Shohei
AU  - Fukunaga, Ami
AU  - Tanaka, Akihito
AU  - Takeuchi, Junko S.
AU  - Inoue, Yosuke
AU  - Kimura, Moto
AU  - Maeda, Kenji
AU  - Ueda, Gohzoh
AU  - Mizoue, Tetsuya
AU  - Ujiie, Mugen
AU  - Sugiura, Wataru
AU  - Ohmagari, Norio
TI  - Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
AID  - 10.1101/2021.07.19.21260744
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.19.21260744
4099  - http://medrxiv.org/content/early/2021/07/22/2021.07.19.21260744.short
4100  - http://medrxiv.org/content/early/2021/07/22/2021.07.19.21260744.full
AB  - High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38□ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers.Competing Interest StatementAntibody test reagents were provided by Abbott Japan. Gohzoh Ueda is an employee of Abbott Japan.Funding StatementThis work was funded by Abbott Japan (grant number 20C050), the NCGM COVID-19 Gift Fund (grant number 19K059), the Japan Health Research Promotion Bureau Research Fund (grant number 2020-B-09), and a grant from the National Center for Global Health (grant number 21A006).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of National Center for the Global Health and Medicine, Japan (the approved number: NCGM-A-004175)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analyzed during the current study are not publicly available due to ethical restrictions and participant confidentiality concerns.